{"generic":"Meningococcal Conjugate\/Haemophilus B Conjugate Vaccine","drugs":["Menhibrix","Meningococcal Conjugate\/Haemophilus B Conjugate Vaccine"],"mono":{"0":{"id":"jxx4s0","title":"Generic Names","mono":"Meningococcal Conjugate\/Haemophilus B Conjugate Vaccine"},"1":{"id":"jxx4s1","title":"Dosing and Indications","sub":{"1":{"id":"jxx4s1b5","title":"Pediatric Dosing","mono":"<b>Hemophilus influenzae type B infection - Meningococcal infectious disease, Neisseria meningitidis serogroups C and Y; Prophylaxis:<\/b> (aged 2 to 18 months) 4-dose series, 0.5 mL IM at 2, 4, 6, and 12 to 15 months of age; may be administered as early as 6 weeks of age; the fourth dose may be given at up to 18 months of age "},"3":{"id":"jxx4s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Hemophilus influenzae type B infection - Meningococcal infectious disease, Neisseria meningitidis serogroups C and Y; Prophylaxis<br\/>"}}},"3":{"id":"jxx4s3","title":"Contraindications\/Warnings","sub":[{"id":"jxx4s3b9","title":"Contraindications","mono":"severe allergic reactions (eg, anaphylaxis) to any Meningococcal-, Haemophilus influenzae type b-, or tetanus toxoid-containing vaccine or any component of product <br\/>"},{"id":"jxx4s3b10","title":"Precautions","mono":"<ul><li>Guillain-Barr  syndrome within 6 weeks of prior tetanus toxoid vaccination; consider risks and benefits<\/li><li>hypersensitivity, including anaphylaxis, may occur; have appropriate supportive medical treatment readily available<\/li><li>immunosuppressed children, including those receiving immunosuppressive therapy; immune response to vaccine may be suboptimal<\/li><li>not a substitute for routine tetanus immunization<\/li><li>premature infants; apnea has been reported following IM vaccination<\/li><li>syncope, with transient neurological signs (eg, visual disturbance, paresthesia, tonic-clonic limb movements), may occur; put procedures in place to avoid falling injury and to restore cerebral perfusion<\/li><li>report suspected adverse reactions to VAERS at 1-800-822-7967 or www.vaers.hhs.gov<\/li><\/ul>"},{"id":"jxx4s3b11","title":"Pregnancy Category","mono":"<ul><li>Haemophilus B Vaccine: C (FDA)<\/li><li>Haemophilus B Vaccine: B2 (AUS)<\/li><li>Meningococcal Vaccine, Tetanus Toxoid Conjugate Bivalent: Unknown<\/li><\/ul>"},{"id":"jxx4s3b12","title":"Breast Feeding","mono":"<ul><li>Haemophilus B Vaccine: Micromedex: Infant risk is minimal.<\/li><li>Meningococcal Vaccine, Tetanus Toxoid Conjugate Bivalent: Unknown<\/li><\/ul>"}]},"4":{"id":"jxx4s4","title":"Drug Interactions","sub":{"1":{"id":"jxx4s4b14","title":"Major","mono":"<ul><li>Cyclosporine (theoretical)<\/li><li>Measles Virus Vaccine, Live (probable)<\/li><\/ul>"}}},"5":{"id":"jxx4s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (any, 20.6% to 35.5%; greater than 30 mm, 0.1% to 0.7%), Injection site pain (United States subset: all grade, 41.4% to 46.2%; grade 3, 1.6% to 3.7%), Swelling at injection site (any, 14.7% to 25.4%; greater than 30 mm, 0.3% to 0.6%)<\/li><li><b>Gastrointestinal:<\/b>Loss of appetite (all grade, 30.1% to 33.8%; grade 3, 0.5% to 1.1%)<\/li><li><b>Neurologic:<\/b>Somnolence (all grade, 48.7% to 62.8%; grade 3, 1.7% to 3.2%)<\/li><li><b>Psychiatric:<\/b>Irritability (all grade, 62.1% to 70.8%; grade 3, 2.5% to 4.8%)<\/li><li><b>Other:<\/b>Fever (United States subset: 100.4 degrees F or higher, 11% to 25.9%; 102.2 degrees F or higher, 1.1% to 3.2%; higher than 104 degrees F, up to 0.3%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Neurologic:<\/b>Seizure<\/li><li><b>Respiratory:<\/b>Apnea of prematurity<\/li><\/ul>"},"6":{"id":"jxx4s6","title":"Drug Name Info","sub":{"0":{"id":"jxx4s6b17","title":"US Trade Names","mono":"Menhibrix<br\/>"},"2":{"id":"jxx4s6b19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"jxx4s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jxx4s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jxx4s7","title":"Mechanism Of Action","mono":"The meningococcal polysaccharide\/haemophilus B conjugate vaccine contains Neisseria meningitidis serogroup C and Y capsular polysaccharide antigens and Haemophilus B capsular polysaccharide (polyribosyl-ribitol-phosphate (PRP)). Administration of the vaccine triggers production of antibodies specific to the capsular polysaccharides of Neisseria meningitidis serogroups C and Y, and antibodies to PRP. The presence of anti-capsular meningococcal and anti-PRP antibodies are associated with protection from invasive meningococcal disease and invasive disease due to Haemophilus influenza type B, respectively.<br\/>"},"9":{"id":"jxx4s9","title":"Administration","mono":"<b>Intramuscular<\/b><br\/><ul><li>Reconstitute with 0.6 mL of accompanying saline diluent only<\/li><li>Shake well<\/li><li>Administer by IM injections immediately following reconstitution<\/li><li>Administer IM injection in the anterolateral aspect of the thigh for children less than 1 year of age; deltoid muscle is usually large enough for an IM injection in older pediatric patients<\/li><\/ul>"},"10":{"id":"jxx4s10","title":"Monitoring","mono":"antibody titers may be indicative of efficacy<br\/>"},"11":{"id":"jxx4s11","title":"How Supplied","mono":"<b>Menhibrix<\/b><br\/>Intramuscular Powder for Solution: (Haemophilus B Conjugate Vaccine - Meningococcal Vaccine, Tetanus Toxoid Conjugate Bivalent) 2.5 MCG<br\/>"},"13":{"id":"jxx4s13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause syncope (fainting), which can be accompanied by visual disturbance, paresthesia, and tonic-clonic limb movements. Instruct caregiver to report occurrence and\/or signs\/symptoms.<\/li><li>This drug may cause irritability, drowsiness, loss of appetite, or fever, as well as injection-site pain, redness, or swelling.<\/li><li>Instruct caregiver to immediately report signs\/symptoms of an allergic reaction to their healthcare provider.<\/li><li>Inform caregiver of the importance of the child receiving the entire series of vaccinations. If a dose is missed, another appointment should be scheduled as soon as possible.<\/li><\/ul>"}}}